治疗B）药物治疗：日本动脉粥样硬化协会（JAS）关于日本动脉粥样硬化性心血管疾病诊断与预防指南——2012版执行摘要 - Suppr

Treatment B) drug therapy: executive summary of the Japan Atherosclerosis Society(JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

作者信息

Teramoto Tamio, Sasaki Jun, Ishibashi Shun, Birou Sadatoshi, Daida Hiroyuki, Dohi Seitaro, Egusa Genshi, Hiro Takafumi, Hirobe Kazuhiko, Iida Mami, Kihara Shinji, Kinoshita Makoto, Maruyama Chizuko, Ohta Takao, Okamura Tomonori, Yamashita Shizuya, Yokode Masayuki, Yokote Koutaro

机构信息

Committee for Epidemiology and Clinical Management of Atherosclerosis.

出版信息

J Atheroscler Thromb. 2013;20(12):850-60. doi: 10.5551/jat.19166. Epub 2013 Dec 10.

DOI:10.5551/jat.19166

PMID:24335039

Abstract

摘要

相似文献

Treatment B) drug therapy: executive summary of the Japan Atherosclerosis Society(JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

J Atheroscler Thromb. 2013;20(12):850-60. doi: 10.5551/jat.19166. Epub 2013 Dec 10.

Treatment A) lifestyle modification: executive summary of the Japan Atherosclerosis Society(JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

J Atheroscler Thromb. 2013;20(12):835-49. doi: 10.5551/jat.18820. Epub 2013 Oct 29.

Women. Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan―2012 Version.

J Atheroscler Thromb. 2014;21(4):291-5. doi: 10.5551/jat.19711. Epub 2013 Dec 10.

Comprehensive risk management for the prevention of cardiovascular disease: executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -- 2012.

J Atheroscler Thromb. 2013;20(7):603-15. doi: 10.5551/jat.15867. Epub 2013 Jul 25.

Diabetes mellitus. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

J Atheroscler Thromb. 2014;21(2):93-8. doi: 10.5551/jat.19349. Epub 2013 Dec 10.

Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.

J Atheroscler Thromb. 2018 Sep 1;25(9):846-984. doi: 10.5551/jat.GL2017. Epub 2018 Aug 22.

Coronary artery disease. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

J Atheroscler Thromb. 2014;21(2):86-92. doi: 10.5551/jat.19158. Epub 2013 Dec 10.

Other types of primary hyperlipoproteinemia(hyperlipidemia). Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

J Atheroscler Thromb. 2014;21(2):82-5. doi: 10.5551/jat.19141. Epub 2013 Dec 10.

Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese.

J Atheroscler Thromb. 2007 Apr;14(2):45-50. doi: 10.5551/jat.14.45.

Cardiovascular disease risk factors other than dyslipidemia. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan - 2012 version.

J Atheroscler Thromb. 2013;20(10):733-42. doi: 10.5551/jat.17368. Epub 2013 Jul 26.

引用本文的文献

Two Patients with Familial Hypercholesterolemia Who Were Successfully Weaned from Low-density Lipoprotein Apheresis after Treatment with Evolocumab.

Intern Med. 2017;56(12):1531-1535. doi: 10.2169/internalmedicine.56.7958. Epub 2017 Jun 15.

Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.

Lipids Health Dis. 2017 Jun 17;16(1):121. doi: 10.1186/s12944-017-0513-7.

Statin use and all-cause and cancer mortality: BioBank Japan cohort.

J Epidemiol. 2017 Mar;27(3S):S84-S91. doi: 10.1016/j.je.2016.12.011. Epub 2017 Feb 11.

Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©.

Patient. 2017 Jun;10(3):321-334. doi: 10.1007/s40271-016-0211-y.

Rationale and Design of the PROSPECTIVE Trial: Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Prior Coronary Heart Disease.

J Atheroscler Thromb. 2016 Jun 1;23(6):746-56. doi: 10.5551/jat.32813. Epub 2016 Jan 22.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Treatment B) drug therapy: executive summary of the Japan Atherosclerosis Society(JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

作者信息

机构信息

Committee for Epidemiology and Clinical Management of Atherosclerosis.

出版信息

J Atheroscler Thromb. 2013;20(12):850-60. doi: 10.5551/jat.19166. Epub 2013 Dec 10.

DOI:10.5551/jat.19166

PMID:24335039

Abstract

摘要

Treatment B) drug therapy: executive summary of the Japan Atherosclerosis Society(JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Treatment B) drug therapy: executive summary of the Japan Atherosclerosis Society(JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

作者信息

机构信息

出版信息

相似文献

引用本文的文献